Treat with enjoyment

Prescribe Luminopia—give children ages 4-7 with amblyopia the choice to watch TV to improve their vision1,2
Scroll to learn more
Photo of child wearing Luminopia VR headset on bean bag

What is Luminopia?

Luminopia is the simple, engaging and effective FDA-approved* amblyopia treatment designed to improve vision in children 4-7 years old.1-3

By prescribing Luminopia, you’re giving patients the opportunity to watch TV for 1 hour a day, 6 days a week instead of wearing an eye patch.1

Our comfortable, lightweight VR headsets display the TV content which keeps patients engaged and distraction-free throughout treatment.1

Luminopia can be prescribed in just a few minutes through PhilRx Pharmacy.
*De novo granted October 2021

How Luminopia works

Unique, dual-acting binocular mechanism encourages both eyes to work together to improve vision

Reducing contrast

to the stronger eye overcomes suppression of the amblyopic eye4

Dichoptic masking

blocks complementary parts of the image for each eye to encourage the brain to combine the videos into one complete image5

The Loud House™
Wild Kratts®
Sponge Bob SquarePants™
Puss in Boots™
Project Mc2™
How To Train Your Dragon™
Dora the Explorer™

Our proprietary software includes 75 shows—that’s 3,100+ episodes of carefully curated content

Kid-friendly shows include favorites such as Sesame Street®, SpongeBob SquarePants™, Wild Kratts®—all without the need for a separate subscription.
Contact a rep to Learn More

Luminopia gives children the freedom to treat their amblyopia from wherever they're most comfortable.

Clinical Data

Proven efficacy and safety


US-based clinical trials





Rapid and sustained vision improvement through 12 weeks1-3†

Rapid and sustained vision improvement with Luminopia: Primary Endpoint Data BCVA
*p<0.05     **p<0.01
Primary endpoint at 12 weeks was met (p=0.001)
† Rapid” is defined as first follow-up at 4 weeks
Control (glasses alone)

Unique, dual-acting binocular mechanism demonstrates significant vision improvement in previously treated patients1-3†

Graph of data depicting vision improvement with Luminopia among previously treated patients
*p<0.05     **p<0.01
Control (glasses alone)
  • There were no serious adverse events reported with Luminopia
  • The most common adverse events reported (treatment vs. control) were headaches (14.3% vs. 1.7%), all graded as mild and transient
  • Cases of new or worsening heterotropia were balanced between groups (7.1% vs. 8.5%), and the rate of all ocular adverse events was similar between groups (11% vs 14%)
  • Rate of all ocular adverse events similar between groups
Includes events classified with possible, probable, or definite relation to study treatment

Children stick with a treatment they enjoy

In the Luminopia clinical trial, the rate of adherence to prescribed treatment was almost double the rate of adherence measured in patching clinical trials.3,6
Median % of total treatment completed
See how easy it is to prescribe Luminopia in just a few minutes
Start Prescribing
Photo of doctor writing Luminopia prescription
Order a Luminopia starter kit to be shipped to your practice
Place Your Order
Photo of Luminopia starter kit

Follow your patients’ progress in the Luminopia Adherence Portal


Our scientific advisors

The collaborative partners in pediatric ophthalmology and neuroscience who helped bring Luminopia to life
Photo of David Hunter
David Hunter, MD, PhD
Ophthalmologist-in-Chief; Richard Robb Chair in Ophthalmology
Photo of Gil Binenbaum
Gil Binenbaum, MD, MSCE
Chief of the Division of Ophthalmology
Photo of Eric Gaier
Eric Gaier, MD, PhD
Assistant Professor of Ophthalmology
Photo of Mark Bear
Mark Bear, PhD
Picower Professor of

“I like to tell families that since this treatment works differently, it could work well for your child—even if they’ve tried other treatments before that have failed.”

Eric Gaier, MD, PhD

Pediatric Neuro-Ophthalmologist and Adult Strabismus Surgeon at Boston Children’s Hospital, Assistant Professor of Ophthalmology, Harvard Medical School